Botulinum Toxin A Injection Treatment in Chronic Pelvic Pain Patients: Open-Label Extension Study and 12-Month...

Area of Science:

• Urogynecology
• Pain Management
• Pelvic Floor Disorders

Background:

• A prior RCT showed botulinum toxin A (BTA) reduced pelvic floor muscle activity but not pain compared to placebo at 26 weeks.
• Chronic pelvic pain (CPP) in women remains a challenge, necessitating evaluation of novel therapeutic combinations.

Purpose of the Study:

• To assess the efficacy of BTA combined with pelvic floor muscle therapy (PFMT) in women with CPP who did not respond to placebo.
• To investigate the long-term outcomes of BTA versus placebo in women with CPP.

Main Methods:

• An open-label extension and long-term follow-up study of an RCT involving women with CPP.
• Placebo nonresponders received BTA injections followed by PFMT.
• Validated questionnaires assessed pain, quality of life, and pelvic floor muscle function up to 12 months.

Main Results:

• BTA injections led to pain improvement in placebo nonresponders, with sustained effects at 12 months.
• Initial responders in the RCT maintained pain improvement for up to 12 months, regardless of whether they received BTA or placebo.
• No serious safety concerns were reported with BTA treatment.

Conclusions:

• BTA treatment is safe for women with CPP.
• Effective BTA or placebo injections combined with PFMT offer sustained benefits for up to one year.
• Further research is needed due to the exploratory nature of these findings.